ngiogenesis, the sprouting of new blood vessels from existing ones, is a complex process that is critical to normal growth and development, but which occurs only in very specific conditions in adults. However, abnormal angiogenic responses can arise during development (eg, hemangioma formation) and in a variety of disease states. These diseases include, but are not limited to cancers in which blood vessels develop to support tumor growth, psoriasis, pulmonary hypertension, arthritis, and vascular retinopathy that can occur in diabetes, sickle cell disease, and other disorders. Multiple therapeutic approaches with varying degrees of success have been or are being developed to limit angiogenesis. Conversely, approaches to promote angiogenesis or the related but distinct process of collateral formation are also of interest for limiting ischemic damage in conditions where insufficient blood supply contributes to the condition or limits recovery, such as in myocardial infarction, stroke and other neurodegenerative conditions, Crohn disease, and others. 1 Thus, advances in our understanding of events that occur at a molecular level to regulate blood vessel formation are of interest in providing future therapeutic targets to control these events.
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Endothelial cells (ECs) form the innermost layer of most nacsent blood vessels (there are some exceptions, such as the cytotrophoblasts that line maternal arteries in the placenta 2 and tumor cells that mimic ECs in some tumor blood vessels 3 ). Angiogenesis involves an orchestration of events that include communication with and disruption of EC interaction with the surrounding extracellular matrix and neighboring cells; intracellular signaling; interplay between ECs, blood cells, and smooth muscle cells; and protease activity that releases matrix-bound angiogenic factorsevents that lead to EC migration, proliferation, and establishment of new blood vessels. Similar elements are involved in blood vessel repair.
Adhesion molecules on ECs that contribute to vessel formation and stability include integrin ␣ v ␤ 3 , which in several models appears to support vascularization associated with tumor growth in mice, 4 rheumatoid arthritis in rabbits, 5 and angiogenesis in a chick chorioallantoic membrane system. 6 Complete absence of this integrin and the related ␣ v ␤ 5 during development may result in compensatory responses, however, because normal and pathological blood vessel development occur unabated in ␤ 3 /␤ 5 Ϫ/Ϫ mice lacking both of these integrins. 7 Endothelial cell-to-cell junctions are maintained by adherens junctions composed of molecules such as vascular endothelial (VE)-cadherin 8 and ADAM15 9 and tight junctions comprising ZO-1, a member of the membraneassociated guanylate kinases family, claudins, occludins, 10 and members of the immunoglobulin (Ig) superfamily of adhesion receptors, such as junctional adhesion molecule-1 (JAM-1). 11 In addition to their adhesive functions, some of these transmembrane proteins, including JAM-1 and ␣ v ␤ 3 , transduce signals that regulate EC behavior in angiogenic assays [12] [13] [14] Jam-1 is a single-chain, type-1 transmembrane receptor most closely related to JAM-2 and JAM-3, which together are part of a larger subfamily of Ig adhesion receptors called the cortical thymocyte Xenopus family. 15, 16 The JAMs contain 2 extracellular Ig-like domains and have molecular weights ranging from 36 to 45 kDa. While JAM-1 is more widely distributed, being found on platelets, ECs, epithelial cells, and neutrophils, JAM-2 and JAM-3 are largely restricted to ECs. 17, 18 Like many other Ig adhesion receptors, JAM-1 binds in a homotypic fashion to JAM-1 on adjacent cells as well as to distinct ligands such as leukocyte ␣ L ␤ 2 . 19 Before the sequence of JAM-1 was known, its first reported function was as a stimulatory molecule on platelets in response to bound antibodies, giving hint to its signal transduction capabilities. 20 Moreover, JAM-1 (as well as JAM-2 and JAM-3) contains a canonical type-II, PDZ-domain-targeting motif that mediates binding to several proteins, such as ZO-1, occludin, and the cell-polarity protein protease-activated receptor 3 (PAR3). [21] [22] [23] More recently, Naik et al 14 showed that JAM-1 physically associates with ␣ v ␤ 3 when the ligand-binding site of ␣ v ␤ 3 is engaged by Arg-Gly-Asp-Ser (RGDS) peptide. These authors further demonstrated that JAM-1 is required for basic fibroblast growth factor (bFGF) signaling, because an antibody against the extracellular domain of JAM-1 or expression of JAM-1 with a mutated cytoplasmic domain prevent bFGF-induced EC proliferation, angiogenesis, mitogen-activated protein kinase activation, and EC tube formation. These results suggest that signaling through JAM-1 is key to bFGF-induced signaling.
In a study reported in this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Naik et al 24 extend these observations by using RNA interference to deplete endogenous JAM-1 in ECs. Expression of VE-cadherin, ZO-1, ␤-catenin, and the ␤ 3 integrin subunit were unaffected in these cells. However, both bFGF-independent and -dependent changes in cell behavior were observed. Even in the absence of bFGF stimulation, membrane-associated actin was reduced in JAM-1-depleted cells without change in the localization of VE-cadherin or ZO-1. Moreover, basal cell adhesion to and spreading on vitronectin, both ␣ v ␤ 3 -dependent events, were significantly diminished. Interestingly, adhesion to fibronectin was unaffected. Most notably, bFGF-stimulated migration on vitronectin, but not fibronectin, was inhibited, as measured in both a haptotactic migration assay and a wound or scrape assay of EC monolayers. As expected, the JAM-1-depleted cells lacked bFGF-induced ERK signaling, which is required for bFGF-induced migration on vitronectin. These results confirm that JAM-1 is critical to both bFGF signaling and ␣ v ␤ 3 function in endothelial cells and place JAM-1 as a candidate target for therapeutic modulation.
The work by Naik et al 24 will likely lead to studies aimed at defining the role of JAM-1 in whole animal models replicating normal and aberrant blood vessel formation, as in tumerogenesis and other states discussed above. It will be interesting to learn whether acute inhibition of JAM-1 versus chronic loss of JAM-1 during development of JAM-1 Ϫ/Ϫ mice will result in similar or distinct phenotypes, as in the ␤ 3 and ␤ 3 /␤ 5 Ϫ/Ϫ mice. 7 The physical and functional connection between ␣ v ␤ 3 and JAM-1 may lead to an understanding of the current controversy surrounding the role of ␣ v ␤ 3 in angiogenesis. While blocking JAM-1 also blocks ␣ v ␤ 3 function, it is unknown whether the reverse occurs, ie, whether blocking ␣ v ␤ 3 also affects JAM-1 adhesive and signaling events. If so, such a scenario might explain why blocking preexisting ␣ v ␤ 3 inhibits angiogenesis, whereas the lack of ␣ v ␤ 3 in ␤ 3 Ϫ/Ϫ mice enables an apparently normal angiogenic response. Perhaps the chronic loss of ␤ 3 has no effect on JAM-1 function such that angiogenesis can proceed normally. While this notion is purely speculative and potential compensatory events in ␤ 3 deficient mice may be complicated, it is apparent that a greater understanding of how JAM-1 regulates bFGF signaling, ␣ v ␤ 3 function, the function of other molecules involved in angiogenesis, and the signaling pathways involved will enhance our overall understanding of blood vessel formation. Such investigations are likely to uncover additional promising therapeutic targets for regulating angiogenic processes.
